Allarity Therapeutics Inc (ALLR) - Total Assets
Based on the latest financial reports, Allarity Therapeutics Inc (ALLR) holds total assets worth $18.26 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Allarity Therapeutics Inc (ALLR) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
Allarity Therapeutics Inc - Total Assets Trend (2013–2025)
This chart illustrates how Allarity Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See ALLR total equity for net asset value and shareholders' equity analysis.
Allarity Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Allarity Therapeutics Inc's total assets of $18.26 Million consist of 98.2% current assets and 1.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 80.4% |
| Accounts Receivable | $895.00K | 4.9% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2013–2025)
This chart illustrates how Allarity Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Allarity Therapeutics Inc.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Allarity Therapeutics Inc's current assets represent 98.2% of total assets in 2025, an increase from 28.0% in 2013.
- Cash Position: Cash and equivalents constituted 80.4% of total assets in 2025, up from 28.0% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 72.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 4.9% of total assets.
Allarity Therapeutics Inc Competitors by Total Assets
Key competitors of Allarity Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
ALTEOGEN Inc
KQ:196170
|
Korea | ₩729.47 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $440.10 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €3.37 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
Allarity Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.13 | 2.06 | 0.35 |
| Quick Ratio | 2.13 | 2.06 | 0.35 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $9.50 Million | $11.50 Million | $-3.69 Million |
Allarity Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Allarity Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.01 |
| Latest Market Cap to Assets Ratio | 1.02 |
| Asset Growth Rate (YoY) | -19.4% |
| Total Assets | $18.26 Million |
| Market Capitalization | $18.71 Million USD |
Valuation Analysis
Above Book Valuation: The market values Allarity Therapeutics Inc's assets above their book value (1.02x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Allarity Therapeutics Inc's assets decreased by 19.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Allarity Therapeutics Inc (2013–2025)
The table below shows the annual total assets of Allarity Therapeutics Inc from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $18.26 Million | -19.39% |
| 2024-12-31 | $22.65 Million | +90.95% |
| 2023-12-31 | $11.86 Million | -18.44% |
| 2022-12-31 | $14.54 Million | -70.70% |
| 2021-12-31 | $49.63 Million | +48.59% |
| 2020-12-31 | $33.40 Million | +5.68% |
| 2019-12-31 | $31.61 Million | -18.10% |
| 2018-12-31 | $38.59 Million | +1744.07% |
| 2017-12-31 | $2.09 Million | -67.98% |
| 2016-12-31 | $6.54 Million | +19.93% |
| 2015-12-31 | $5.45 Million | +5741.35% |
| 2014-12-31 | $93.30K | -48.16% |
| 2013-12-31 | $180.00K | -- |
About Allarity Therapeutics Inc
Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology. Its lead d… Read more